Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1179 studies found for:    irinotecan
Show Display Options
Rank Status Study
1 Completed Irinotecan (Camptosar) in Patients With Advanced Sarcomas
Condition: Sarcoma
Intervention: Drug: Irinotecan
2 Unknown  Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Condition: Small Cell Lung Cancer
Intervention: Drug: irinotecan
3 Active, not recruiting Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: Irinotecan and Bortezomib
4 Withdrawn A Protocol of Irinotecan for Carcinoma of the Lung
Condition: Lung Cancer
Intervention: Drug: Irinotecan
5 Terminated Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Irinotecan
6 Terminated CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CS-1008;   Drug: irinotecan
7 Completed Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Conditions: Gastrointestinal Cancer;   Carcinoma, Neuroendocrine
Interventions: Drug: Cisplatin;   Drug: Irinotecan
8 Active, not recruiting Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: Bevacizumab, Irinotecan and Temozolomide
9 Completed Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Intervention: Drug: irinotecan hydrochloride
10 Completed Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC
Condition: Breast Cancer Metastatic
Intervention: Drug: Irinotecan plus capecitabine
11 Terminated OSI-906 and Irinotecan in Patients With Advanced Cancer
Condition: Colorectal Cancer
Interventions: Drug: OSI-906;   Drug: irinotecan
12 Completed Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
Conditions: Adenocarcinoma;   Gastric Cancer
Intervention: Drug: irinotecan
13 Completed Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)
Conditions: Leukemia;   Lymphoma
Intervention: Drug: Irinotecan
14 Recruiting Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Radiation: CyberKnife
15 Completed
Has Results
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab;   Drug: Irinotecan
16 Recruiting Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients
Condition: ColoRectal Cancer
Interventions: Drug: Irinotecan;   Drug: Raltitrexed
17 Terminated
Has Results
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
Condition: Colorectal Cancer
Intervention: Drug: cetuximab with irinotecan
18 Unknown  Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents
Condition: Acute Leukemia
Intervention: Drug: Irinotecan
19 Unknown  Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer
Condition: Colonic Neoplasms
Intervention: Drug: Irinotecan
20 Terminated Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
Condition: Malignant Gliomas
Interventions: Drug: Irinotecan;   Drug: Lenalidomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.